Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
Recruiting
N/A
Interventional Study
Multiple Sclerosis
Clinically Isolated Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 150 (estimated)
- Sponsor
- University Hospital, Bordeaux · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* male or female subjects ;
* Age ≥ 18 years;
* subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome;
* patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose;
* …
Contacts